PL374325A1 - Bursztyniany 5,8,14-triazatetracyklo[10.3.1.0 2,11 .0 4,9]-heksadeka-2(11),3,5,7,9-pentaenu i ich środki farmaceutyczne - Google Patents
Bursztyniany 5,8,14-triazatetracyklo[10.3.1.0 2,11 .0 4,9]-heksadeka-2(11),3,5,7,9-pentaenu i ich środki farmaceutyczneInfo
- Publication number
- PL374325A1 PL374325A1 PL02374325A PL37432502A PL374325A1 PL 374325 A1 PL374325 A1 PL 374325A1 PL 02374325 A PL02374325 A PL 02374325A PL 37432502 A PL37432502 A PL 37432502A PL 374325 A1 PL374325 A1 PL 374325A1
- Authority
- PL
- Poland
- Prior art keywords
- triazatetracyclo
- pentaene
- hexadeca
- pharmaceutical compositions
- succinic acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33424501P | 2001-11-29 | 2001-11-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL374325A1 true PL374325A1 (pl) | 2005-10-17 |
Family
ID=23306297
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL02374325A PL374325A1 (pl) | 2001-11-29 | 2002-10-21 | Bursztyniany 5,8,14-triazatetracyklo[10.3.1.0 2,11 .0 4,9]-heksadeka-2(11),3,5,7,9-pentaenu i ich środki farmaceutyczne |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US6794388B2 (pl) |
| EP (1) | EP1461040B1 (pl) |
| JP (1) | JP4196829B2 (pl) |
| KR (1) | KR20040066140A (pl) |
| CN (1) | CN1589148A (pl) |
| AR (1) | AR037677A1 (pl) |
| AT (1) | ATE320256T1 (pl) |
| AU (1) | AU2002341327A1 (pl) |
| BR (1) | BR0214559A (pl) |
| CA (1) | CA2468705A1 (pl) |
| DE (1) | DE60209929T2 (pl) |
| DO (1) | DOP2002000512A (pl) |
| ES (1) | ES2258652T3 (pl) |
| GT (1) | GT200200236A (pl) |
| HN (1) | HN2002000332A (pl) |
| IL (1) | IL161326A0 (pl) |
| MX (1) | MXPA04003192A (pl) |
| PA (1) | PA8559401A1 (pl) |
| PE (1) | PE20030738A1 (pl) |
| PL (1) | PL374325A1 (pl) |
| RU (1) | RU2004116311A (pl) |
| SV (1) | SV2004001413A (pl) |
| TW (1) | TW200300345A (pl) |
| UY (1) | UY27548A1 (pl) |
| WO (1) | WO2003045394A1 (pl) |
| ZA (1) | ZA200402720B (pl) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ME00459B (me) * | 1997-12-31 | 2011-10-10 | Pfizer Prod Inc | Aril fuzirana azapoliciklična jedinjenja |
| WO2004096286A2 (en) | 2003-04-25 | 2004-11-11 | Gilead Sciences, Inc. | Antiviral phosphonate analogs |
| MXPA05012507A (es) * | 2003-05-20 | 2006-01-30 | Pfizer Prod Inc | Composiciones farmaceuticas de vareniclina. |
| NZ546447A (en) * | 2003-10-27 | 2009-02-28 | Merck & Co Inc | ((1R,3S)-3-isopropyl-3-{[3-(trifluoromethyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl]carbonyl}cyclopentyl)[(3S,4S)-3-methoxytetrahydro-2H-pyran-4-yl]amine succinate |
| ES2363160T3 (es) | 2004-07-27 | 2011-07-22 | Gilead Sciences, Inc. | Conjugados de fosfonato nucelosidico como agentes anti-vih. |
| US20110086086A1 (en) * | 2005-07-26 | 2011-04-14 | Pfizer Inc | Transdermal system for varenicline |
| KR100734147B1 (ko) * | 2005-07-29 | 2007-07-02 | 주식회사 엘지데이콤 | 호 알림 지연을 통한 멀티미디어 통화연결음 서비스 시스템및 방법 |
| KR101424832B1 (ko) * | 2006-05-16 | 2014-08-06 | 길리애드 사이언시즈, 인코포레이티드 | 악성 혈액 종양 치료 방법 및 악성 혈액 종양 치료용 조성물 |
| BRPI0718600A2 (pt) * | 2006-11-09 | 2013-12-10 | Pfizer Prod Inc | Polimorfos de intermediários nicotínicos. |
| KR20090092338A (ko) * | 2006-12-21 | 2009-08-31 | 화이자 프로덕츠 인크. | 2-((4-(1-메틸-4-(피리딘-4-일)-1ｈ-피라졸-3-일)페녹시)메틸)퀴놀린의 숙시네이트 염 |
| WO2009109651A1 (en) * | 2008-03-06 | 2009-09-11 | Medichem, S.A. | SALTS OF A PYRAZINO[2,3-h][3]BENZAZEPINE DERIVATIVE |
| WO2009143347A2 (en) | 2008-05-22 | 2009-11-26 | Teva Pharmaceutical Industries Ltd. | Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate |
| US20090318460A1 (en) * | 2008-05-26 | 2009-12-24 | Glenmark | Amorphous varenicline tartrate and process for the preparation thereof |
| AU2009268681B2 (en) | 2008-07-08 | 2014-10-02 | Gilead Sciences, Inc. | Salts of HIV inhibitor compounds |
| US20100010221A1 (en) * | 2008-07-10 | 2010-01-14 | Revital Lifshitz-Liron | Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt |
| WO2010033045A1 (en) * | 2008-09-16 | 2010-03-25 | Igor Anatolievich Pomytkin | Compositions and methods for prevention or treatment of beta amyloid deposition |
| WO2010068181A1 (en) * | 2008-12-11 | 2010-06-17 | S*Bio Pte Ltd | 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6)1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27)j16,21,23-decaene citrate salt |
| WO2010143070A2 (en) | 2009-06-10 | 2010-12-16 | Actavis Group Ptc Ehf | Amorphous varenicline tartrate co-precipitates |
| US8178537B2 (en) | 2009-06-22 | 2012-05-15 | Teva Pharmaceutical Industries Ltd. | Solid state forms of varenicline salts and processes for preparation thereof |
| WO2011140431A1 (en) | 2010-05-06 | 2011-11-10 | Teva Pharmaceutical Industries Ltd. | Varenicline salts and crystal forms thereof |
| WO2013163917A1 (zh) | 2012-04-13 | 2013-11-07 | 连云港金康和信药业有限公司 | 化合物jk12a及其制备 |
| EP3209295B2 (en) | 2014-10-20 | 2023-12-06 | Oyster Point Pharma, Inc. | Methods of treating ocular conditions |
| IL299204A (en) | 2016-04-07 | 2023-02-01 | Oyster Point Pharma Inc | Methods for treating eye conditions |
| WO2019027920A1 (en) | 2017-08-01 | 2019-02-07 | Gilead Sciences, Inc. | CRYSTALLINE FORMS OF ETHYL ((S) - (((((2R, 5R) -5- (6-AMINO-9H-PURIN-9-YL) -4-FLUORO-2,5-DIHYDROFURAN-2-YL) OXY ) METHYL) (PHENOXY) PHOSPHORYL) -L-ALANINATE (GS-9131) FOR THE TREATMENT OF VIRAL INFECTIONS |
| WO2018154395A2 (en) | 2018-06-11 | 2018-08-30 | Alvogen Malta Operations (Row) Ltd | Controlled release pharmaceutical composition of varenicline |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ME00459B (me) * | 1997-12-31 | 2011-10-10 | Pfizer Prod Inc | Aril fuzirana azapoliciklična jedinjenja |
| DE60036950T2 (de) | 1999-08-27 | 2008-08-07 | Inex Pharmaceuticals Corp., Burnaby | Zusammensetzungen zur stimulation der zytokin sekretion und zur induktion einer immunantwort |
| CZ20011726A3 (cs) * | 2000-05-26 | 2002-02-13 | Pfizer Products Inc. | Způsob reakční krystalizace, který umoľňuje řídit velikost částic |
-
2002
- 2002-10-21 KR KR10-2004-7008116A patent/KR20040066140A/ko not_active Application Discontinuation
- 2002-10-21 CN CNA028229304A patent/CN1589148A/zh active Pending
- 2002-10-21 JP JP2003546896A patent/JP4196829B2/ja not_active Expired - Fee Related
- 2002-10-21 PL PL02374325A patent/PL374325A1/pl not_active Application Discontinuation
- 2002-10-21 EP EP02775143A patent/EP1461040B1/en not_active Expired - Lifetime
- 2002-10-21 BR BRPI0214559-6A patent/BR0214559A/pt not_active IP Right Cessation
- 2002-10-21 WO PCT/IB2002/004380 patent/WO2003045394A1/en active IP Right Grant
- 2002-10-21 RU RU2004116311/04A patent/RU2004116311A/ru not_active Application Discontinuation
- 2002-10-21 ES ES02775143T patent/ES2258652T3/es not_active Expired - Lifetime
- 2002-10-21 DE DE60209929T patent/DE60209929T2/de not_active Expired - Fee Related
- 2002-10-21 MX MXPA04003192A patent/MXPA04003192A/es active IP Right Grant
- 2002-10-21 CA CA002468705A patent/CA2468705A1/en not_active Abandoned
- 2002-10-21 AT AT02775143T patent/ATE320256T1/de not_active IP Right Cessation
- 2002-10-21 IL IL16132602A patent/IL161326A0/xx unknown
- 2002-10-21 AU AU2002341327A patent/AU2002341327A1/en not_active Abandoned
- 2002-11-13 DO DO2002000512A patent/DOP2002000512A/es unknown
- 2002-11-22 GT GT200200236A patent/GT200200236A/es unknown
- 2002-11-25 PE PE2002001130A patent/PE20030738A1/es not_active Application Discontinuation
- 2002-11-25 TW TW091134190A patent/TW200300345A/zh unknown
- 2002-11-26 UY UY27548A patent/UY27548A1/es not_active Application Discontinuation
- 2002-11-27 AR ARP020104558A patent/AR037677A1/es unknown
- 2002-11-27 US US10/305,845 patent/US6794388B2/en not_active Expired - Fee Related
- 2002-11-27 HN HN2002000332A patent/HN2002000332A/es unknown
- 2002-11-28 SV SV2002001413A patent/SV2004001413A/es not_active Application Discontinuation
- 2002-11-29 PA PA20028559401A patent/PA8559401A1/es unknown
-
2004
- 2004-04-07 ZA ZA200402720A patent/ZA200402720B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002341327A1 (en) | 2003-06-10 |
| CN1589148A (zh) | 2005-03-02 |
| WO2003045394A1 (en) | 2003-06-05 |
| TW200300345A (en) | 2003-06-01 |
| DE60209929D1 (de) | 2006-05-11 |
| CA2468705A1 (en) | 2003-06-05 |
| EP1461040B1 (en) | 2006-03-15 |
| ES2258652T3 (es) | 2006-09-01 |
| UY27548A1 (es) | 2003-06-30 |
| SV2004001413A (es) | 2004-05-07 |
| JP4196829B2 (ja) | 2008-12-17 |
| PE20030738A1 (es) | 2003-08-28 |
| GT200200236A (es) | 2003-06-25 |
| PA8559401A1 (es) | 2004-02-07 |
| ZA200402720B (en) | 2005-05-18 |
| DE60209929T2 (de) | 2006-11-16 |
| DOP2002000512A (es) | 2003-05-31 |
| HN2002000332A (es) | 2003-12-11 |
| MXPA04003192A (es) | 2004-07-27 |
| ATE320256T1 (de) | 2006-04-15 |
| RU2004116311A (ru) | 2005-03-27 |
| IL161326A0 (en) | 2004-09-27 |
| JP2005513032A (ja) | 2005-05-12 |
| AR037677A1 (es) | 2004-12-01 |
| KR20040066140A (ko) | 2004-07-23 |
| US6794388B2 (en) | 2004-09-21 |
| US20030149044A1 (en) | 2003-08-07 |
| BR0214559A (pt) | 2007-03-13 |
| EP1461040A1 (en) | 2004-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL374325A1 (pl) | Bursztyniany 5,8,14-triazatetracyklo[10.3.1.0 2,11 .0 4,9]-heksadeka-2(11),3,5,7,9-pentaenu i ich środki farmaceutyczne | |
| EG24228A (en) | Tartrate salts of 5,8,18-trizatetracyclo[010.3.1.0.0]hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof | |
| PL370913A1 (pl) | Środki farmaceutyczne zawierajace 5,7,14-triazatetracyklo [10.3.1.0(2,11).0(4,9)] heksadeka-2(11) 3,5,7,9-pentaen | |
| HUP0302656A3 (en) | Fumaric acid amides, their use for preparation of pharmaceutical compositions and pharmaceutical compositions containing the compounds | |
| HUP0303148A3 (en) | 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity, pharmaceutical compositions containing the compounds and processes for their preparation | |
| HUP0401567A3 (en) | Novel 4,5-dyhydro-1h-pyrazole derivatives having cb1-antagonistic activity, their use and pharmaceutical compositions containing them | |
| IL161431A0 (en) | beta-PHENYL-alpha-OXYSUBSTITUTED PROPIONIC ACID DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | |
| HUP0700086A2 (en) | 2-aminopyridine compounds, use thereof as drugs and pharmaceutical compositions containing them | |
| PL367242A1 (pl) | Pochodne N-(arylosulfonylo)-beta-aminokwasów zawierające podstawioną grupę aminometylową, sposób ich wytwarzania i zawierające je środki farmaceutyczne | |
| HK1067626A1 (en) | Novel 2h-pyridazine-3-one derivatives, pharmaceutical compositions containing the same and a process for the preparation of the active ingredient | |
| HUP0400246A3 (en) | 1,2,4-trioxolane antimalarial pharmaceutical compositions and process for their preparation and use | |
| HUP0304085A3 (en) | The citrate salt of 5,8,14-triazatetracyclo(10.3.1.02,11.04,9)-hexadeca-2.(11),3,5,7,9-pentaene and pharmaceutical compositions thereof | |
| HUP0401403A3 (en) | 2,4-diaminothiazole derivatives, their use and pharmaceutical compositions containing them | |
| WO2003024933A1 (fr) | Derive d'acide 2-phenyle-3-heteroarylpropionique ou son sel et medicaments le contenant | |
| HUP0600084A2 (en) | Pharmaceutical compositions containing ascorbic acid derivatives, methods of production of the active ingredient | |
| HUP0401713A3 (en) | Aralkyl-tetrahydro-pyridines, their preparation and pharmaceutical compositions containing same | |
| HUP0200729A3 (en) | Hydroxamic acid derivatives, their use and preparation and pharmaceutical compositions containing them | |
| PT1358159E (pt) | Tartrato e fosfato de 3,4 diaminopiridina, as suas composições farmacêuticas e as suas utilizações | |
| HK1046284A1 (en) | Polymorphs of crystalline azabicyclo(2,2,2)octan-3-aminecitrate and their pharmaceutical compositions. | |
| IL158587A0 (en) | Novel 5-thio-ss-d-xylopyranoside derivatives, preparation method thereof, pharmaceutical compositions containing same and the therapeutic use thereof | |
| HUP0200605A3 (en) | Hydroxamic acid derivatives, their preparation and use and pharmaceutical compositions containing them | |
| AU2002308369A1 (en) | 1-butane acid derivatives, pharmaceutical compositions containing said derivatives and the use thereof | |
| HUP0400800A3 (en) | Substituted 5,6,6a,11b-tetrahydro-7-oxa-5-aza-benzo[c]fluorene-6-carboxylic acid derivatives, process for their preparation, their use and pharmaceutical compositions containing them | |
| HUP0402424A3 (en) | Imidazoquinoline derivatives, process for their preparation and pharmaceutical compositions containing the same | |
| HU0100987D0 (en) | New propenecarboxylic acid amidoxime derivatives, process for their preparation and pharmaceutical compositions containing them |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |